{"id":1499,"company":{"country":"AU","currency":"AUD","exchange":"ASX - ALL MARKETS","ipo":"1999-04-30","marketCap":19.36285972595215,"name":"Immuron Ltd","phone":"61398245254.0","outstanding":227.79800415039062,"symbol":"IMRN","website":"https://www.immuron.com.au","industry":"Biotechnology"},"price":2.055,"year":2023,"month":12,"day":9,"weekday":"Saturday","title":"Historical Performance of Immuron Ltd Stock","date":"2023-12-09","url":"/posts/2023/12/09/IMRN","content":[{"section":"Introduction","text":"Immuron Ltd is a biopharmaceutical company that focuses on developing and commercializing oral immunotherapy products. To assess its historical stock performance, we will compare it against industry benchmarks, which are typically broad market indices or sector-specific indices."},{"section":"Methodology","text":"For this analysis, we will compare Immuron Ltd's stock performance to the performance of a relevant industry benchmark over a specific time period. The benchmark will serve as a proxy to measure the performance of the overall industry or market. We will consider factors such as stock price movements, total return, and volatility."},{"section":"Comparison and Findings","text":"Upon comparing Immuron Ltd's stock performance to the industry benchmark, we found the following:"},{"section":"1. Stock Price Movements","text":"Immuron Ltd's stock price may have experienced upward or downward movements during the analyzed period. The benchmark will show whether these movements were in line with broader market trends or specific to the company."},{"section":"2. Total Return","text":"Total return takes into account both capital appreciation (increase in stock price) and dividends or distributions received by shareholders. We will assess Immuron Ltd's total return compared to the benchmark to determine its relative performance."},{"section":"3. Volatility","text":"Volatility measures the extent to which a stock's price fluctuates. A comparison of Immuron Ltd's volatility to the benchmark will provide insights into its risk profile and price stability compared to the industry or market as a whole."},{"section":"Conclusion","text":"By analyzing Immuron Ltd's historical performance compared to industry benchmarks, we can gain valuable insights into its relative performance, risk profile, and overall market trends. This analysis helps to maintain objectivity and provides context for evaluating the company's stock performance."},{"section":"Note","text":"Please note that specific historical data and findings are not provided in this generic analysis. It is recommended to refer to actual data and conduct detailed analysis for accurate and up-to-date information."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1701687600,"headline":"Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study","id":124276480,"image":"https://media.zenfs.com/en/globenewswire.com/f93b8574aa2211fc81545c76eeb2a3a7","symbol":"IMRN","publisher":"Yahoo","summary":"Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting volunteers against moderate to severe campylobacteriosisNew CampETEC product is a prophylactic therapeutic designed to protect against Campylobacter and Enterotoxigenic Escherichia coli (ETEC) infections, two of the major causes of Travelers’ diarrhea The in-patient stage of the study is anticipated to be","url":"https://finance.yahoo.com/news/immuron-announces-first-patients-enrolled-110000365.html"},{"category":"company","date":1701666360,"headline":"Immuron says first patients enrolled in Campylobacter challenge clinical study","id":124282325,"image":"","symbol":"IMRN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240294473"},{"category":"company","date":1701171180,"headline":"Immuron CEO, Steven Lydeamore Investor Webinar Presentation","id":124146464,"image":"https://media.zenfs.com/en/globenewswire.com/f93b8574aa2211fc81545c76eeb2a3a7","symbol":"IMRN","publisher":"Yahoo","summary":"MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar “Coffee Microcaps Morning Meeting”, to be held on Thursday, 30th of November, 2023, 9:00am ADEST. CEO Steven Lydeamore will provide an overview and update on the business and upcoming milestones. Following the presentation, attendees will have the opportunity to ask q","url":"https://finance.yahoo.com/news/immuron-ceo-steven-lydeamore-investor-113300846.html"}]}